NewAmsterdam Pharma (NAMS) Short term Debt (2022 - 2026)

NewAmsterdam Pharma has disclosed Short term Debt across 5 years of filings, most recently posting $50.2 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $50.2 million, up 113.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.2 million (up 113.53% YoY), and the FY2025 annual result was $57.3 million, up 52.67% from the prior year.
• Short term Debt came in at $50.2 million for Q1 2026 at NewAmsterdam Pharma, down from $57.3 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $57.3 million in Q4 2025 to a low of $8414.1 in Q2 2023.
• The 5-year median for Short term Debt is $23.5 million (2024), against an average of $27.2 million.
• Across the five-year window, Short term Debt jumped 279727.28% in 2024 and declined 28.85% in 2025, its largest moves.
• NewAmsterdam Pharma's Short term Debt stood at $4.0 million in 2022, then jumped by 216.99% to $12.6 million in 2023, then soared by 198.35% to $37.5 million in 2024, then surged by 52.67% to $57.3 million in 2025, then fell by 12.3% to $50.2 million in 2026.
• The last three Short term Debt figures came in at $50.2 million (Q1 2026), $57.3 million (Q4 2025), and $44.4 million (Q3 2025), per Business Quant data.